When was Replay founded?

Replay was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Replay located?

Replay is headquartered in San Diego, United States.

How many employees does Replay have?

As of Mar 31, 2026, the latest employee count at Replay is 32.

Is Replay a funded company?

Replay is a funded company, having raised a total of $55M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 25, 2022.

When was the latest funding round of Replay?

Replay's latest funding was a $***** Grant (prize money) round on Nov 28, 2022, with participation from 1 investor.

Where does Replay rank among its competitors?

Replay ranks 236th amongst 1294 active competitors, of which 288 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of Replay?

Replay's top competitors include Alnylam, Sana Biotechnology and Spark Therapeutics. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

Replay - 2026 Company Profile, Team, Funding & Competitors

Replay is an acquired company based in San Diego (United States), founded in 2021 by Adrian Woolfson, David Knipe and Ron Weiss. It operates as a Provider of genomic reprogramming platform for writing and delivering big DNA. Replay has raised $55M in funding from KKR and OMX Ventures. The company has 1294 active competitors, including 288 funded and 215 that have exited. Its top competitors include companies like Alnylam, Sana Biotechnology and Spark Therapeutics.

Company Details

Provider of genomic reprogramming platform for writing and delivering big DNA. It offers proprietary technology platforms, synHSV - a high payload capacity HSV vector able to deliver up to 30x the payload of AAV, uCell - a universal, renewable, off-the-shelf, genomically rewritten, hypoimmunogenic iPSC-derived cell source for regenerative medicine and cell therapy, DropSynth - a genome writing platform, LASR inference algorithm platform for rewriting proteins to optimize the functionality.

Website: replay.bio
Social
Email ID: *****@replay.bio

Key Metrics

Founded Year

2021

Location

San Diego, United States

Stage

Acquired

Total Funding

$55M in 2 rounds

Latest Funding Round

Grant (prize money), Nov 28, 2022, $*****

Investors

KKR & 7 more

Ranked

236^th among 1294 active competitors

Employee Count

32 as on Mar 31, 2026

Similar Companies

Alnylam & 845 more

Exit Details

Acquired by LEO Pharma (Apr 30, 2026)

View Replay's full profile

Replay is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Replay Holdings, LLC CIN: 83-1807898 , United States, Active	Dec 31, 2020	-	13 (As on Dec 31, 2021)	-

Replay got acquired by LEO Pharma on Apr 30, 2026.

Click here to take a look at Replay's acquisition in detail

Replay has raised a total funding of $55M over 2 rounds. Its first funding round was on Jul 25, 2022. Its latest funding round was a Grant (prize money) round on Nov 28, 2022 for $*****. 1 investor participated in its latest round. Replay has 8 institutional investors.

Here is the list of recent funding rounds of Replay:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 28, 2022	8345264	Grant (prize money)	7015604	6450245	1337027	1909287
Jul 25, 2022	8011308	Seed	1829812	8895725	KKR & 1 more	Artis Ventures & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Replay's funding rounds and investors

The founders of Replay are Adrian Woolfson, David Knipe and Ron Weiss. Lachlan MacKinnon is the CEO of Replay.

Here are the details of Replay's key team members:

Adrian Woolfson: Former Co-Founder of Replay.
David Knipe: Co-Founder of Replay.
Ron Weiss: Co-Founder of Replay.

View details of Replay's Founder profiles and Board Members

Replay's employee count trend

Replay has 32 employees as of Mar 26. Here is Replay's employee count trend over the years:

Uncover Replay's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Replay include Alnylam, Sana Biotechnology and Spark Therapeutics. Here is the list of Top 10 competitors of Replay, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	79/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Wellington & 6 others	74/100
4th	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Google Ventures, Foresite Capital & 15 others	71/100
5th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
6th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Google Ventures & 18 others	70/100
7th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	70/100
8th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 9 others	69/100
9th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 2 others	69/100
236th	Replay 2021, San Diego (United States), Acquired	Provider of genomic reprogramming platform for writing and delivering big DNA	$55M	Artis Ventures, KKR & 6 others	58/100